

Please amend the application as follows:

In the Specification

Please insert the following between the title and Field of the Invention:

Al
This application represents the national stage of PCT international application number WO99/15672, filed September 15, 1998, which claims priority from U.S. provisional patent application serial number 60/059,552, filed September 19, 1997.

In the Claims

Please cancel Claims 2 and 4. Please also cancel Claims 5-11 as drawn to nonelected groups.

Please amend Claim 1 as follows:

AA contd.
1. (Amended) An isolated, recombinantly-generated, attenuated, human respiratory syncytial virus (RSV) subgroup B having at least one attenuating mutation in the RNA polymerase gene, wherein the at least one attenuating mutation in the RNA polymerase gene is selected from the group consisting of nucleotide changes which produce changes in an amino acid selected from the group consisting of residues 353 (arginine → lysine), 451 (lysine → arginine), 1229 (aspartic acid → asparagine), 2029 (threonine → isoleucine) and 2050 (asparagine → aspartic